Gene · 3601
Papers2,328
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
241 to 260 of 2,328
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Transcriptome Analysis Identifies the Crosstalk between Dendritic and Natural Killer Cells in Human Cutaneous Leishmaniasis. | Microorganisms | 2023 | 37630497 | PubTator, text mining | PubMed |
| Signaling Pathways Leading to mTOR Activation Downstream Cytokine Receptors in Lymphocytes in Health and Disease. | Int J Mol Sci | 2023 | 37628917 | PubTator, text mining | PubMed |
| BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer: Current Treatment Landscape and Novel Emerging Molecular Targets. | Int J Mol Sci | 2023 | 37628785 | PubTator, text mining | PubMed |
| Update on the Pathogenesis of Enteropathy-Associated T-Cell Lymphoma. | Diagnostics (Basel) | 2023 | 37627888 | PubTator, text mining | PubMed |
| IL-15 synergizes with CD40 agonist antibodies to induce durable immunity against bladder cancer. | Proc Natl Acad Sci U S A | 2023 | 37607227 | PubTator, text mining | PubMed |
| NKG2D promotes CD8 T cell-mediated cytotoxicity and is associated with treatment failure in human cutaneous leishmaniasis. | PLoS Negl Trop Dis | 2023 | 37603573 | PubTator, text mining | PubMed |
| Study on the cytokines related to SARS-Cov-2 in testicular cells and the interaction network between cells based on scRNA-seq data. | Open Life Sci | 2023 | 37589002 | PubTator, text mining | PubMed |
| Developing drugs targeting CX3CL1 to treat heart diseases via immune/inflammatory mediation. | Acta Biochim Biophys Sin (Shanghai) | 2023 | 37580951 | PubTator, text mining | PubMed |
| In Vivo Zymosan Treatment Induces IL15-Secreting Macrophages and KLRG1-Expressing NK Cells in Mice. | Molecules | 2023 | 37570749 | PubTator, text mining | PubMed |
| IL-15 armoring enhances the antitumor efficacy of claudin 18.2-targeting CAR-T cells in syngeneic mouse tumor models. | Front Immunol | 2023 | 37564658 | PubTator, text mining | PubMed |
| Chimeric antigen receptor engineered natural killer cells for cancer therapy. | Exp Hematol Oncol | 2023 | 37563648 | PubTator, text mining | PubMed |
| Differences in the inflammatory proteome of East African and Western European adults and associations with environmental and dietary factors. | Elife | 2023 | 37555575 | PubTator, text mining | PubMed |
| BET in hematologic tumors: Immunity, pathogenesis, clinical trials and drug combinations. | Genes Dis | 2023 | 37554207 | PubTator, text mining | PubMed |
| Effects of Short- And Medium-Term Exposures to Lower Air Temperature on 71 Novel Biomarkers of Subclinical Inflammation: Results from the KORA F4 Study. | Environ Sci Technol | 2023 | 37552838 | PubTator, text mining | PubMed |
Inhibition of MC38 colon cancer growth by multicomponent chemoimmunotherapy with anti-IL-10R antibodies, HES-MTX nanoconjugate, depends on application of IL-12, IL-15 or IL-18 secreting dendritic cell vaccines. | Front Immunol | 2023 | 37545526 | PubTator, text mining | PubMed |
| Multiple TMA-aided CRISPR/Cas13a platform for highly sensitive detection of IL-15 to predict immunotherapeutic response in nasopharyngeal carcinoma. | J Immunother Cancer | 2023 | 37536937 | PubTator, text mining | PubMed |
| M1/M2 macrophages and their overlaps - myth or reality? | Clin Sci (Lond) | 2023 | 37530555 | PubTator, text mining | PubMed |
| Which is the Ideal JAK Inhibitor for Alopecia Areata - Baricitinib, Tofacitinib, Ritlecitinib or Ifidancitinib - Revisiting the Immunomechanisms of the JAK Pathway. | Indian Dermatol Online J | 2023 | 37521227 | PubTator, text mining | PubMed |
| Comprehensive Analysis and Drug Modulation of Human Endogenous Retrovirus in Hepatocellular Carcinomas. | Cancers (Basel) | 2023 | 37509325 | PubTator, text mining | PubMed |
| Prospective epigenome and transcriptome analyses of cord and peripheral blood from preterm infants at risk of bronchopulmonary dysplasia. | Sci Rep | 2023 | 37507442 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/3601/papers?page=13